Generics BulletinFor the third time, the Federal Trade Commission has sent out warning letters to drug companies, disputing improperly listed patents in the US Food and Drug Administration’s Orange Book. In this round
Generics BulletinLast week’s J.P. Morgan Healthcare Conference in San Francisco generated multiple headlines for the generics and biosimilars industry, with Generics Bulletin bringing you dedicated stories on the la
Generics BulletinAmphastar is continuing in its shift towards a more proprietary portfolio through the development of new products with different delivery systems, as discussed in a fireside chat at this year’s Jeffer
Generics BulletinAmphastar Pharmaceuticals has reported boosted net revenue in its first quarter of 2024, which was driven by sales and payments linked to the hypoglycemia treatment Baqsimi (glucagon) that was acquir